Literature DB >> 20552680

Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood.

Chad A Bousman1, Gursharan Chana, Stephen J Glatt, Sharon D Chandler, Todd May, James Lohr, William S Kremen, Ming T Tsuang, Ian P Everall.   

Abstract

Several brain- and blood-based gene expression studies in patients with psychotic disorders (e.g., schizophrenia) have identified genes in the ubiquitin proteasome system (UPS) pathway as putative biomarkers. However, to date an examination of the UPS pathway in the broader context of symptom severity in psychosis has not been conducted. The purpose of this study was to investigate the correlation between clinical scores on the Scales for the Assessment of Positive and Negative Symptoms (SAPS-SANS) and expression of 43 highly annotated genes within the UPS pathway in blood from patients with psychosis. A sample of 19 psychotic patients diagnosed with schizophrenia (n = 13) or bipolar disorder (n = 6) were recruited. Pearson's partial correlations, adjusting for gender, ethnicity, age, education, medication, smoking, and past 6-month substance use, were performed between each of the selected UPS genes and both scales. Significant Bonferroni-adjusted positive associations were observed between SAPS scores and two ubiquitin conjugation genes (i.e., UBE2K, SIAH2), while a negative association was observed with one deubiquitination gene (i.e., USP2). No gene expression levels were significantly associated with scores on the SANS after correction for multiple testing. Our findings suggest that dysregulation of the UPS, specifically ubiquitin conjugation and deubiquitination, may point to a possible underlying biological mechanism for severity of positive but not negative symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552680      PMCID: PMC4461056          DOI: 10.1002/ajmg.b.31106

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  31 in total

Review 1.  Ubiquitin-mediated proteolysis: biological regulation via destruction.

Authors:  A Ciechanover; A Orian; A L Schwartz
Journal:  Bioessays       Date:  2000-05       Impact factor: 4.345

2.  Polyglutamine tracts in schizophrenia: gaining new insights.

Authors:  I Denghien; R Joober; G A Rouleau; C Néri
Journal:  Mol Psychiatry       Date:  2000-05       Impact factor: 15.992

3.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 4.  Lymphocytes as a neural probe: potential for studying psychiatric disorders.

Authors:  Anatoliy Gladkevich; Henk F Kauffman; Jakob Korf
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-05       Impact factor: 5.067

5.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.

Authors:  J Fuchs; C Nilsson; J Kachergus; M Munz; E-M Larsson; B Schüle; J W Langston; F A Middleton; O A Ross; M Hulihan; T Gasser; M J Farrer
Journal:  Neurology       Date:  2007-01-24       Impact factor: 9.910

Review 6.  Deubiquitinating enzymes: a new class of biological regulators.

Authors:  A D'Andrea; D Pellman
Journal:  Crit Rev Biochem Mol Biol       Date:  1998       Impact factor: 8.250

7.  Polyglutamine-containing proteins in schizophrenia.

Authors:  R Joober; C Benkelfat; M Jannatipour; G Turecki; S Lal; J L Mandel; D Bloom; P Lalonde; I Lopes-Cendes; D Fortin; G Rouleau
Journal:  Mol Psychiatry       Date:  1999-01       Impact factor: 15.992

8.  Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells.

Authors:  Ruth Rott; Raymonde Szargel; Joseph Haskin; Vered Shani; Alla Shainskaya; Irena Manov; Esti Liani; Eyal Avraham; Simone Engelender
Journal:  J Biol Chem       Date:  2007-12-10       Impact factor: 5.157

9.  Molecular evidence for mitochondrial dysfunction in bipolar disorder.

Authors:  Christine Konradi; Molly Eaton; Matthew L MacDonald; John Walsh; Francine M Benes; Stephan Heckers
Journal:  Arch Gen Psychiatry       Date:  2004-03

10.  Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples.

Authors:  Chad A Bousman; Gursharan Chana; Stephen J Glatt; Sharon D Chandler; Ginger R Lucero; Erick Tatro; Todd May; James B Lohr; William S Kremen; Ming T Tsuang; Ian P Everall
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

View more
  21 in total

1.  Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms.

Authors:  S Mas; P Gassó; E Parellada; M Bernardo; A Lafuente
Journal:  Pharmacogenomics J       Date:  2015-01-27       Impact factor: 3.550

Review 2.  An integrative functional genomics approach for discovering biomarkers in schizophrenia.

Authors:  Marquis P Vawter; Firoza Mamdani; Fabio Macciardi
Journal:  Brief Funct Genomics       Date:  2011-12-08       Impact factor: 4.241

3.  Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations.

Authors:  C Liu; C A Bousman; C Pantelis; E Skafidas; D Zhang; W Yue; I P Everall
Journal:  Transl Psychiatry       Date:  2017-02-21       Impact factor: 6.222

4.  Protein Expression of Proteasome Subunits in Elderly Patients with Schizophrenia.

Authors:  Madeline R Scott; Maria D Rubio; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2015-07-23       Impact factor: 7.853

Review 5.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

6.  Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia.

Authors:  María D Rubio; Krista Wood; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-04-09       Impact factor: 7.853

7.  A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes.

Authors:  Simone de Jong; Marco P M Boks; Tova F Fuller; Eric Strengman; Esther Janson; Carolien G F de Kovel; Anil P S Ori; Nancy Vi; Flip Mulder; Jan Dirk Blom; Birte Glenthøj; Chris D Schubart; Wiepke Cahn; René S Kahn; Steve Horvath; Roel A Ophoff
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

8.  Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.

Authors:  Gursharan Chana; Chad A Bousman; Tammie T Money; Andrew Gibbons; Piers Gillett; Brian Dean; Ian P Everall
Journal:  Front Cell Neurosci       Date:  2013-06-26       Impact factor: 5.505

Review 9.  A common STEP in the synaptic pathology of diverse neuropsychiatric disorders.

Authors:  Micah A Johnson; Paul J Lombroso
Journal:  Yale J Biol Med       Date:  2012-12-13

10.  Negative Symptoms of Psychosis Correlate with Gene Expression of the Wnt/β-Catenin Signaling Pathway in Peripheral Blood.

Authors:  Chad A Bousman; Stephen J Glatt; Sharon D Chandler; James Lohr; William S Kremen; Ming T Tsuang; Ian P Everall
Journal:  Psychiatry J       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.